This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The National Organization for the Reform of Marijuana Laws (NORML) has formally submitted comments to the US Federal Register opposing the Drug Enforcement Administration’s proposed rule changes governing the federal production and distribution of cannabis for clinical research purposes.
On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.
A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinicaltrials involving cannabis. Click here to send a message to your Representative and urge them to support the measure. . The agency ultimately rejected her decision.
Currently, the sole federally licensed producer of cannabis for clinical research is the University of Mississippi. ” Last year, however, former DEA director Robert Patterson testified to Congress that the agency believed that approving additional applicants would likely violate international anti-drug treaties. .”
Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle.
The Denver cannabis company MedPharm can now ramp up its research into the effects marijuana has on Alzheimer’s disease. The new DEA research license will now change that. It’s possible because of a new Schedule I Researcher License granted by the Drug Enforcement Administration. credit: CBS).
A federal court on Friday denied a petition for a writ of mandamus that sought to order the US Drug Enforcement Administration to begin licensing private entities that wish to cultivate cannabis. The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinicaltrials.
The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year. Marijuana itself would get a 60 percent boost under DEA’s proposal, up to 3.2 Imagine reading that headline in 1980!
Legislation unanimously passed by members of the US Senate empowers the US Attorney General to facilitate clinical research trials involving cannabis. NORML write. The action represents one of the very few occasions that members of the Senate have ever advanced a marijuana-related reform bill.
Much of the argument, before Circuit Judges Mark Bennett, Sandra Ikuta and Ryan Nelson, focused on whether the DEA’s conclusion that it could not waive any part of the federal Controlled Substances Act (CSA), which bans psilocybin except for limited research purposes, could even be appealed. Forty-one states have passed such laws.
This Act permits individuals that have been diagnosed with life-threatening conditions or diseases that have exhausted all other approved treatment and therapeutic options that are also unable to participate in clinicaltrials the ability to access certain treatments that would otherwise be unapproved for access.
The reality that most high-schoolers have easier access to cannabis than do our nation’s top scientists is the height of absurdity and an indictment of the current system.”. “These common-sense regulatory changes are necessary and long overdue.
Drug Enforcement Agency (DEA) to cultivate marijuana for research purposes. In 2016, Dr. Sue Sisley first applied to grow cannabis for research purposes when the Obama administration announced a plan to allow other growers to provide cannabis to researchers. Use the plants for their own studies and/or FDA clinicaltrials.
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. ”We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.”
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinicaltrial.
The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. Some states in the U.S.
Attorneys representing a cannabis biopharma conglomerate and federal cannabis cultivation license applicant filed a petition in court today, citing that the Drug Enforcement Agency (DEA) is taking too long to issue a determination for its application. . Breaking Exclusive: Another Cannabis Company Sues the DEA.
Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Drug Enforcement Agency (DEA).
As the cannabis industry continues to grow and evolve with legalization achieved in many parts of the world, we’re seeing an increase in activity related to another substance that will hopefully be removed from the list of controlled substances – psilocybin. Additional clinicaltrials underway in the U.S.
In the United States, most cannabis research to date has focused on the potential harms of the plant, instead of its benefits. funders use their money for cannabis research. His findings are sure to alarm medical cannabis professionals and patients alike. WHY ISN’T MORE RESEARCH DONE ON CANNABIS THERAPEUTICS?
Recently, we’ve been getting tons of questions from clients regarding the international import and export of cannabis around the globe. 2018 was a historic year for the cannabis industry not just in the United States, but also internationally. If imported cannabis products are allowed into the U.S., Many countries (e.g.,
Bank of America (BoA) is reportedly terminating its banking relationship with Scottsdale Research Institute (SRI), a DEA-registered facility that carries out important marijuana research. The quality of this cannabis had been criticised by a number of researchers, including Dr. Sisley.
CANNABIS CULTURE – The results are now in after the first-ever legal clinicaltrial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? That’s what most providers are worried about when their patients with PTSD decide to try cannabis.”.
Similar to ketamine, psilocybin has shown great promise in clinicaltrials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). According to the Feds, ketamine is safer than cannabis (which is a Schedule I controlled substance).
– because today’s post is a deep dive into everything you need to know about the most popular cannabis compound around. Let’s clear up one of the biggest sources of confusion right off the bat: CBD is a cannabis compound called cannabidiol. Researchers believe cannabis contains over 100 unique chemical compounds!
None of the approved drugs contain, or are derived from, the whole cannabis plant. a Canada-based medical cannabis firm. “It rapidly destigmatizes what cannabis can do.” Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree.
This is the first time a research license for this type of work has been granted outside of state and city research licenses to study cannabis. . Thanks to the new DEA research license, MedPharm will now be able to supply investigational medications across state lines for the purpose of clinicaltrials.
Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinicaltrials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , ClinicalTrial ID NCT03866174, available at [link].
MAPS, The Multidisciplinary Association for Psychedelic Substances, was awarded a $12,979,050 million grant from the state of Michigan to fund a study on PTSD and cannabis on August 10. This grant enables more rigorous study, overseen by the FDA, which may lead to cannabis flower becoming prescribable medicine someday.
The only psychedelic drug that is approved (outside of clinicaltrials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Though, Oregon is actively in the process of establishing a model for psilocybin that would be like the state’s current medical cannabis system. Schedule I.
LAS VEGAS, NV [August 16, 2021] – Cannabis Conference , produced by parent company GIE Media Inc. Dr. Sisley will highlight cutting-edge discoveries from her roles in cannabis studies for pain management and post-traumatic stress disorder (PTSD), as a substitution therapy for opioids, and more. 25 from 11 a.m. –
Because most delta-8 products are derived from hemp plants, it is believed by some that they fall under a loophole in federal cannabis laws. The cannabis plant can produce a great number of active compounds — those unique to cannabis are called cannabinoids. Drug test for cannabis. It is also touted as natural and safe.
A multitude of recent clinicaltrials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. This is a policy where the federal government, the DEA, will refrain from taking prosecutorial action if state law permits, regulates, and carefully controls the use of a drug.
This year, we are completing the second Phase 3 clinicaltrial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,
Similar to the early days of the medical cannabis movement, psychedelic drugs such as MDMA, psilocybin, LSD, ketamine and DMT are being developed for therapeutic use in a complex and difficult legal and regulatory environment. The firm’s multidisciplinary team covers commercial, regulatory and legal requirements spanning U.S. Steve Levine.
601 , the “Medical Cannabis Research Act of 2019” H.R. 601, Medical Cannabis Research Act of 2019. CLICK IMAGE TO ACCESS COMMITTEE INFO PAGE. Legislation. 171 , the “Legitimate Use of Medicinal Marihuana Act” or the “LUMMA” H.R. 2843, Marijuana Freedom and Opportunity Act.
The sale will greatly reduce the current and future burn rate of the company and allow it to focus on achieving profitability, seeking a DEA license, and implementing GMP, a set of regulations promulgated by the U.S.
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinicaltrials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment.
The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). The rollercoaster starts here!
The drug has previously been used with some success in clinicaltrials designed to treat depression. These trials typically involve the use of music playlists to support the psychedelic experience.
Selling dried cannabis to pharmaceutical companies as well as Cannabidiol (CBD) and Tetrahydrocannabinol (THC) extracts as soon as it is licensed, is the intention of Thailand’s tobacco authority among new measures to turn a profit on its dwindling cigarette business. TOAT, the First Thai Cannabis Money Maker.
Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinicaltrials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).
It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. Within a few months, it had completed the first phase of its clinicaltrial of DMT in combination with supportive psychotherapy and commenced a phase 2a trial. Small Pharma (CVE: DMT ) (OTCMKTS: DMTTF ).
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content